1. Non-alcoholic fatty liver disease: relationship with cardiovascular risk markers and clinical endpoints
- Author
-
Simon D. Taylor-Robinson, E. Louise Thomas, Francesca M. Trovato, Nader Lessan, Adam Buckley, and Guglielmo M. Trovato
- Subjects
0301 basic medicine ,Endocrinology, Diabetes and Metabolism ,Disease ,0302 clinical medicine ,Endocrinology ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,MAGNETIC-RESONANCE ,Clinical endpoint ,Brachial artery ,Carotid intima-media thickness ,METABOLIC SYNDROME ,GENERAL-POPULATION ,NAFLD and Diabetes ,medicine.diagnostic_test ,Fatty liver ,General Medicine ,Cardiovascular risk markers ,PREVALENCE ,Cardiovascular Diseases ,Liver biopsy ,CAROTID ATHEROSCLEROSIS ,Disease Progression ,030211 gastroenterology & hepatology ,Life Sciences & Biomedicine ,INSULIN-RESISTANCE ATHEROSCLEROSIS ,medicine.medical_specialty ,Surrogate markers of cardiovascular disease ,Endocrinology & Metabolism ,03 medical and health sciences ,Fatty liver disease ,medicine.artery ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,medicine ,Humans ,HEPATIC STEATOSIS ,Risk factor ,Science & Technology ,business.industry ,nutritional and metabolic diseases ,DIABETES-MELLITUS ,1103 Clinical Sciences ,NAFLD FIBROSIS SCORE ,medicine.disease ,digestive system diseases ,030104 developmental biology ,NAFLD screening process ,Metabolic syndrome ,FOLLOW-UP ,business ,Biomarkers - Abstract
Non-alcoholic fatty liver disease (NAFLD) is a common diagnosis and is increasing in prevalence worldwide. NAFLD is usually asymptomatic at presentation; progression of the disease is unpredictable, leading to the development of a variety of techniques for screening, diagnosis and risk stratification. Clinical methods in current use include serum biomarker panels, hepatic ultrasound, magnetic resonance imaging, and liver biopsy. NAFLD is strongly associated with the metabolic syndrome, and the most common cause of death for people with the condition is cardiovascular disease. Whether NAFLD is an independent cardiovascular risk factor needs exploration. NAFLD has been associated with surrogate markers of cardiovascular disease such as carotid intima-media thickness, the presence of carotid plaque, brachial artery vasodilatory responsiveness and CT coronary artery calcification score. There is no effective medical treatment for NAFLD and evidence is lacking regarding the efficacy of interventions in mitigating cardiovascular risk. Health care professionals managing patients with NAFLD should tackle the issue with early identification of risk factors and aggressive modification. Current management strategies therefore comprise lifestyle change, with close attention to known cardiovascular risk factors.
- Published
- 2018
- Full Text
- View/download PDF